Sign In
Buy GKOS
$152.72
+0 (+0%)
At Close: Jul 13, 2026
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
05:03pm, Wednesday, 08'th Jul 2026
Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized fo
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
03:05pm, Wednesday, 08'th Jul 2026
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
This Glaucoma Therapy Company Is Keeping An Eye On Profits
12:22pm, Wednesday, 08'th Jul 2026
This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
07:00am, Wednesday, 08'th Jul 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. Wi
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
07:00am, Thursday, 25'th Jun 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
03:16pm, Friday, 05'th Jun 2026
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
Glaukos Announces Participation in Upcoming Investor Conferences
07:00am, Tuesday, 12'th May 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
11:55am, Thursday, 30'th Apr 2026
GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
11:21pm, Wednesday, 29'th Apr 2026
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:00pm, Wednesday, 29'th Apr 2026
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare t
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
07:41pm, Wednesday, 29'th Apr 2026
Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.
Glaukos Announces First Quarter 2026 Financial Results
04:05pm, Wednesday, 29'th Apr 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
11:26am, Thursday, 16'th Apr 2026
GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.
Glaukos Announces the Release of its 2025 Sustainability Report
07:00am, Thursday, 16'th Apr 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
